Newest disclosures first · Trade dates may be earlier
Loading insider disclosures…
Sources & coverage
These are available SEC Form 4 purchase and sale records. The view excludes awards, gifts, option exercises and other transaction types. Large shareholders can include investment firms as well as individuals.
The period follows filing dates. Each row also shows when the transaction occurred. Reported value is shares multiplied by the reported price; a missing or zero imported price is shown as unavailable.
Weekly highlights cover the last seven filing dates and count distinct reporting-owner names. They feature the largest purchase and sale totals among companies with complete amounts in the available records, independently of the filters below.
Coverage is partial. Expand a transaction for the reporting owners, ownership, trading-plan disclosure and footnotes available in that record. Older records may only identify the first reporting owner. Missing context is shown as unavailable; the original filing remains the source.
Role filters use reported officer titles and ownership relationships, so one filing can match more than one role. A purchase transaction code does not establish that a trade took place on the open market.
Position & filing details for Hoffman Michael B, ANVS, filed Nov 6, 2026
Added 148.6% to reported shares3,364,883 before → 8,364,883 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Hoffman Michael B · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The 5,000,000 shares of Common Stock and 5,000,000 warrants described in Table I and Table II, respectively, were acquired for a combined price of $1.00 per share.
F2 The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
Position & filing details for Skelly Noreen E, ROAD, filed Nov 6, 2026
Added 2.9% to reported shares3,434 before → 3,534 after
Change in this reported indirect Class A Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Skelly Noreen E · Director
Filing facts
Security
Class A Common Stock
Ownership
Indirect · By Skelly Revocable Trust
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The reported shares are held by a trust for which the reporting person serves as co-trustee, and in such capacity shares the power to vote and direct the disposition of such shares.
F2 Includes 8,000 restricted shares of Class A common stock, $0.001 par value, of Construction Partners, Inc. with time-based vesting criteria previously granted to the reporting person under the Construction Partners, Inc. 2018 Equity Incentive Plan that vest as follows: (i) 5,333 shares on January 1, 2027 and (ii) 2,667 shares on January 1, 2028. Under the terms of the award agreement, the reporting person has sole voting power with respect to the shares.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for KINDER RICHARD D, KMI, filed Nov 6, 2026
Added 0.20% to reported shares246,212,353 before → 246,712,353 after
Change in this reported direct Class P Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
KINDER RICHARD D · Executive Chairman · Director · 10% owner
Filing facts
Security
Class P Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.92 to $29.99 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Position & filing details for Equels Thomas K, AIM, filed Nov 6, 2026
Added 10.7% to reported shares189,747 before → 210,046 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Chowbey Sanjay, KMT, filed Nov 6, 2026
Added 2.6% to reported shares273,957.373 before → 280,957.373 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Chowbey Sanjay · President and CEO · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $23.79, inclusive. The reporting person undertakes to provide to Kennametal Inc., any security holder of Kennametal Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4
Position & filing details for MOORTHY GANESH, GFS, filed Nov 6, 2026
Added 83.3% to reported shares3,000 before → 5,500 after
Change in this reported direct Ordinary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
MOORTHY GANESH · Director
Filing facts
Security
Ordinary Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 This transaction represents an open market purchase of issuer's ordinary shares by the reporting person.
Position & filing details for Epstein David R, AGMB, filed Nov 6, 2026
Added 16.7% to reported shares30,000 before → 35,000 after
Change in this reported direct Common shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Epstein David R · Director
Filing facts
Security
Common shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Position & filing details for Epstein David R, AGMB, filed Nov 6, 2026
Added 14.3% to reported shares35,000 before → 40,000 after
Change in this reported direct Common shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Epstein David R · Director
Filing facts
Security
Common shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Position & filing details for Epstein David R, AGMB, filed Nov 6, 2026
Added 20% to reported shares25,000 before → 30,000 after
Change in this reported direct Common shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Epstein David R · Director
Filing facts
Security
Common shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Position & filing details for IRICK JAIME A, TRNS, filed Nov 6, 2026
New reported position0 before → 2,275 after
A percentage increase is undefined when the previously reported holding was zero. This describes the direct position on this filing, not total beneficial ownership.
Reporting owner
IRICK JAIME A · President and CEO · Director
Filing facts
Security
Common Stock, $.50 par value
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $100.89 to $101.35. The reporting person undertakes to provide to Transcat, Inc., any security holder of Transcat, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 These restricted stock units, which convert into common stock on a one-for-one basis, vest on March 31, 2029, except as otherwise provided in the award notice.
KY
KYNKayne Anderson Energy Infrastructure Fund, Inc.
Baker James CPresident
Purchase$331,085Added 2.5% to reported shares25,000 shares · $13.24 / share
Position & filing details for Baker James C, KYN, filed Nov 6, 2026
Added 2.5% to reported shares1,003,019 before → 1,028,019 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Dai Kun, UXIN, filed Nov 6, 2026
Added 5.2% to reported shares160,695 before → 169,002 after
Change in this reported indirect American depositary shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Dai Kun · Chief Executive Officer · Director
Filing facts
Security
American depositary shares
Ownership
Indirect · By Xin Gao Group Limited
Trading plan
Indicated on this filing
Form
4
Filing footnotes
F1 Each American depositary shares represents 300 Class A ordinary shares of the issuer.
Position & filing details for WANG CHUN KAI, OWLS, filed Nov 6, 2026
Added 0.01% to reported shares3,148,105 before → 3,148,505 after
Change in this reported direct Class A Common Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
WANG CHUN KAI · Chief Executive Officer · Director
Filing facts
Security
Class A Common Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price of US$2.3550. These shares were purchased in multiple transactions at prices ranging from US$2.3100 to US$2.3700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Position & filing details for Alvord Christina M, APOG, filed Nov 6, 2026
Added 0.57% to reported shares9,113 before → 9,165 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Alvord Christina M · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Represents shares of common stock acquired through the automatic reinvestment of a cash dividend in the reporting person's brokerage account.
Position & filing details for Klein Gal Nir, SYNX, filed Nov 6, 2026
Added 16.5% to reported shares60,149 before → 70,089 after
Change in this reported direct Ordinary Shares, no par value per share position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Klein Gal Nir · VP Marketing & Israel Sales · Director
Filing facts
Security
Ordinary Shares, no par value per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Held as joint tenants with right of survivorship with Mrs. Klein's spouse, Mr. Nir Klein, who is also a reporting person of Silynxcom Ltd. (the "Issuer"), and over which they share control and pecuniary interest.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 3, 2026 at prices ranging from $0.9500 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for Sturm Len, DFH, filed Nov 6, 2026
Added 3.3% to reported shares30,728 before → 31,728 after
Change in this reported direct Class A common stock, par value $0.01 per share position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Sturm Len · Director
Filing facts
Security
Class A common stock, par value $0.01 per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. The prices purchased ranged from $10.50 to $10.56. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for Kleiser Kirk E., CLST, filed Nov 6, 2026
Added 1.6% to reported shares45,887 before → 46,601 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kleiser Kirk E. · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Includes 1,696 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that reflect the unvested portion of a grant amount originally covering 8,464 shares that commenced vesting 20% per year on September 1, 2023.
F2 Includes 847 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that reflect the unvested portion of a grant amount originally covering 1,058 shares that commenced vesting 20% per year on June 10, 2026.
Position & filing details for Kiai Parsa, MED, filed Nov 6, 2026
Added 3.2% to reported shares20,428 before → 21,089 after
Change in this reported indirect Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kiai Parsa · Director
Filing facts
Security
Common Stock
Ownership
Indirect · Notes
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Ownership of Steamboat Capital Partners II, LP (II).
F2 Steamboat Capital Partners GP, LLC (GP) is general partner of, and entitled to receive a performance allocation from II. Parsa Kiai ("Kiai") is the Managing Member of GP. Accordingly, Kiai may be deemed to have a pecuniary interest in the shares owned by II. Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein.
Position & filing details for Kleiser Kirk E., CLST, filed Nov 6, 2026
Added 4.9% to reported shares20,099 before → 21,089 after
Change in this reported indirect Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership; indirect interests may overlap other reported holdings.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Kleiser Kirk E. · Director
Filing facts
Security
Common Stock
Ownership
Indirect · By IRA
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Includes 1,696 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that reflect the unvested portion of a grant amount originally covering 8,464 shares that commenced vesting 20% per year on September 1, 2023.
F2 Includes 847 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that reflect the unvested portion of a grant amount originally covering 1,058 shares that commenced vesting 20% per year on June 10, 2026.
Position & filing details for Wang Jiawei, FFAI, filed Nov 6, 2026
New reported position0 before → 1 after
A percentage increase is undefined when the previously reported holding was zero. This describes the direct position on this filing, not total beneficial ownership.
Reporting owner
Wang Jiawei · Executive Chairman · Director
Filing facts
Security
Series A Preferred Stock, par value $0.0001 per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 On November 5, 2026, the Reporting Person purchased one (1) share of Series A Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of the Issuer from the Issuer for cash consideration of $100.00. The Preferred Stock has the rights, preferences, privileges and restrictions set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock filed by the Issuer with the Secretary of State of the State of Delaware (the "Series A COD").
Position & filing details for Klein Nir, SYNX, filed Nov 6, 2026
Added 0.35% to reported shares2,812,794 before → 2,822,734 after
Change in this reported direct Ordinary Shares, no par value per share position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Klein Nir · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares, no par value per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Represents 2,752,645 shares held by Mr. Klein as an individual, and 60,149 shares as joint tenants with right of survivorship with Mr. Klien's spouse, Mrs. Gal Nir Klein, who is also a reporting person of Silynxcom Ltd. (the "Issuer"), and over which they share control and pecuniary interest.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 3, 2026 at prices ranging from $0.9500 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for Mudick Stephanie B, TBBK, filed Nov 6, 2026
Added 2.3% to reported shares44,150 before → 45,150 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Williams Eugene, PMN, filed Nov 6, 2026
Added 193.2% to reported shares13,713 before → 40,213 after
Change in this reported direct Common Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for BAKER BROS. ADVISORS LP, MDGL, filed Nov 6, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
BAKER BROS. ADVISORS LP · Director
Baker Bros. Advisors (GP) LLC · Director
BAKER FELIX · Director
BAKER JULIAN · Director
667, L.P. · Director
Baker Brothers Life Sciences LP · Director
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See Footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
Position & filing details for GOVE SUE, LKQ, filed Nov 6, 2026
Added 89.1% to reported shares10,998 before → 20,793 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Klein Gal Nir, SYNX, filed Nov 6, 2026
Added 19.9% to reported shares50,149 before → 60,149 after
Change in this reported direct Ordinary Shares, no par value per share position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Klein Gal Nir · VP Marketing & Israel Sales · Director
Filing facts
Security
Ordinary Shares, no par value per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Held as joint tenants with right of survivorship with Mrs. Klein's spouse, Mr. Nir Klein, who is also a reporting person of Silynxcom Ltd. (the "Issuer"), and over which they share control and pecuniary interest.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 3, 2026 at prices ranging from $0.9500 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for Klein Nir, SYNX, filed Nov 6, 2026
Added 0.36% to reported shares2,802,794 before → 2,812,794 after
Change in this reported direct Ordinary Shares, no par value per share position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Klein Nir · Chief Executive Officer · Director
Filing facts
Security
Ordinary Shares, no par value per share
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Represents 2,752,645 shares held by Mr. Klein as an individual, and 60,149 shares as joint tenants with right of survivorship with Mr. Klien's spouse, Mrs. Gal Nir Klein, who is also a reporting person of Silynxcom Ltd. (the "Issuer"), and over which they share control and pecuniary interest.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 3, 2026 at prices ranging from $0.9500 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for Rey David A, FICO, filed Nov 6, 2026
Added 0.16% to reported shares5,053 before → 5,061 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Rey David A · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The Reporting Person has agreed to disgorge to the Issuer all statutory "profits" pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, that resulted from the transactions reported herein and such amount has been paid to the Issuer.
Position & filing details for Francos Guillermo Alberto, YPF, filed Nov 6, 2026
Added 25% to reported shares27,700 before → 34,630 after
Change in this reported direct American Depositary Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Rey David A, FICO, filed Nov 6, 2026
Added 0.16% to reported shares5,053 before → 5,061 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Rey David A · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The Reporting Person has agreed to disgorge to the Issuer all statutory "profits" pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, that resulted from the transactions reported herein and such amount has been paid to the Issuer.
Position & filing details for GORDON CARL L, ETRA, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
GORDON CARL L · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Indirect · See footnotes
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F2 These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
Position & filing details for Parsons Landon, AOMR, filed Nov 5, 2026
Added 14.8% to reported shares49,832 before → 57,232 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Parsons Landon · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Includes the current grant of 11,737 shares of unvested restricted stock that vest on May 13, 2027 subject to the reporting person's continued service to the issuer through the applicable vesting date.
Position & filing details for Novogratz Michael, GLXY, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
Novogratz Michael · Chief Executive Officer · Director · 10% owner
Galaxy Group Investments LLC · 10% owner
Jointly reported holdings can overlap.
Filing facts
Security
Class A Common Stock
Ownership
Indirect · Held by Galaxy Group Funding ECI U LLC
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for MOORE JOHN A, SCND, filed Nov 5, 2026
Added 0.99% to reported shares1,008,941 before → 1,018,941 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for GORDON CARL L, ETRA, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owner
GORDON CARL L · Director · 10% owner
Filing facts
Security
Common Stock
Ownership
Indirect · See footnotes
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F2 These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
Position & filing details for Novogratz Michael, GLXY, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
Novogratz Michael · Chief Executive Officer · Director · 10% owner
Galaxy Group Investments LLC · 10% owner
Jointly reported holdings can overlap.
Filing facts
Security
Class A Common Stock
Ownership
Indirect · Held by Galaxy Group Funding ECI U LLC
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Position & filing details for ORBIMED ADVISORS LLC, ETRA, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
ORBIMED ADVISORS LLC · Director · 10% owner
OrbiMed Capital GP VII LLC · Director · 10% owner
OrbiMed Genesis GP LLC · Director · 10% owner
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
Position & filing details for Carey Thomas D., LAB, filed Nov 5, 2026
Added 21.8% to reported shares344,456 before → 419,456 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
Position & filing details for Ali Wajid, TTMI, filed Nov 5, 2026
Added 27.9% to reported shares35,835 before → 45,835 after
Change in this reported direct Common Stock position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
Ali Wajid · Director
Filing facts
Security
Common Stock
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $63.04 - $63.25, inclusive. The reporting person undertakes to provide to TTM Technologies, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Position & filing details for ORBIMED ADVISORS LLC, ETRA, filed Nov 5, 2026
Position percentage unavailable
This filing does not establish an unambiguous before-and-after direct holding for this transaction.
Reporting owners
ORBIMED ADVISORS LLC · Director · 10% owner
OrbiMed Capital GP VII LLC · Director · 10% owner
OrbiMed Genesis GP LLC · Director · 10% owner
Jointly reported holdings can overlap.
Filing facts
Security
Common Stock
Ownership
Indirect · See footnotes
Trading plan
Not indicated on this filing
Form
4
Record limitations
Multiple reporting owners appear in this filing; their interests may overlap.
Filing footnotes
F1 These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
Position & filing details for RICE RONALD A, MTUS, filed Nov 5, 2026
Added 6.6% to reported shares151,818 before → 161,818 after
Change in this reported direct Common Shares position, measured against shares held before this transaction. It is not a change in total beneficial ownership.
The filing includes footnotes that may qualify these reported figures; you can review them below.
Reporting owner
RICE RONALD A · Director
Filing facts
Security
Common Shares
Ownership
Direct
Trading plan
Not indicated on this filing
Form
4
Filing footnotes
F1 Price reported is the weighted average purchase price for shares purchased by the reporting owner on November 5, 2026. Shares were purchased at a variety of prices ranging from $16.12 to $16.85.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 4, 2026 at prices ranging from $0.9750 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F3 Includes 1,058 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that vest at 20% per year commencing on June 10, 2027.
F4 The options vest at a rate of 20% per year commencing on June 10, 2027.
F5 The options are vesting at a rate of 20% per year commenced on September 1, 2023.
F6 The options are vesting at a rate of 20% per year commenced on June 10, 2026.
F3 This is an average price. Actual prices paid for the shares purchased on 11/04/26 and reported on this line range from $12.87 to $13.15. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes 1,058 shares granted pursuant to the Issuer's 2022 Recognition and Retention Plan and Trust Agreement that vest at 20% per year commencing on June 10, 2027.
F4 The options vest at a rate of 20% per year commencing on June 10, 2027.
F5 The options are vesting at a rate of 20% per year commenced on September 1, 2023.
F6 The options are vesting at a rate of 20% per year commenced on June 10, 2026.
F3 Represents 2,752,645 shares held by Mr. Klein as an individual, and 70,089 shares as joint tenants with right of survivorship with Mr. Klien's spouse, Mrs. Gal Nir Klein, who is also a reporting person of the Issuer, and over which they share control and pecuniary interest.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 4, 2026 at prices ranging from $0.9750 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
F4 Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") and 454 shares of Common Stock underlying unvested RSUs previously granted to each of Julian C. Baker, a managing member of the Adviser GP, and Dr. Raymond Cheong, a full-time employee of the Adviser, in their capacity as directors of the Issuer.
F5 The price reported in Column 4 is a weighted average price. These shares of Common Stock were traded by Life Sciences in multiple transactions at prices ranging from $366.77 to $367.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
F7 Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the board of directors of the Issuer and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
F8 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F9 The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $367.41 to $368.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 4, 2026 at prices ranging from $0.9750 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 Represents 2,752,645 shares held by Mr. Klein as an individual, and 70,089 shares as joint tenants with right of survivorship with Mr. Klien's spouse, Mrs. Gal Nir Klein, who is also a reporting person of the Issuer, and over which they share control and pecuniary interest.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions on November 4, 2026 at prices ranging from $0.9750 to $1.0000 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
F2 Galaxy Group Funding ECI U LLC is wholly-owned by Galaxy Group Investments LLC, which is controlled by the Reporting Person.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.371 to $13.870 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 Includes 327,065 shares of Class A Common Stock to be delivered in settlement of restricted share unit awards ("RSUs"), subject to continued service through the applicable vesting date.
F5 Each RSU represents the right to receive one share of Class A common stock.
F3 Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
F2 Galaxy Group Funding ECI U LLC is wholly-owned by Galaxy Group Investments LLC, which is controlled by the Reporting Person.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.371 to $13.870 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 Includes 327,065 shares of Class A Common Stock to be delivered in settlement of restricted share unit awards ("RSUs"), subject to continued service through the applicable vesting date.
F5 Each RSU represents the right to receive one share of Class A common stock.
F2 These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
F3 This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
F2 These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
F3 This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
